HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Food Firm Stands Its Ground After FDA Repeats Recall Request

This article was originally published in The Rose Sheet

Executive Summary

Primus Pharmaceuticals say an insert in packages of its Limbrel capsules prescribed to manage metabolic processes associated with osteoarthritis advises that the ingredient baicalin could cause the lung condition acute hypersensitive pneumonitis and elevated liver enzymes in users with allergies to the flavonoid.

You may also be interested in...



Primus Has Experts' Support But Agrees With FDA To Recall Medical Food

Primus Pharmaceuticals voluntarily recalls unexpired lots of its Limbrel medical food available in 250 and 500 mg capsules. Other recent nutritional product sector recalls include Bulletproof 360's protein dietary supplement after a labeling error omitted milk as an ingredient.

Medical Food Firm's Production Investigated After Rash Of Adverse Events

FDA receives 194 adverse event reports regarding Primus Pharmaceuticals''s Limbrel medical food capsules, including two about "potentially life-threatening medical conditions." The agency says a likely relation was found between the product and the conditions reported in 30 of the AERs.

Curecumin Piques US Consumers’ Interest; UK Curiosity Grows For Omega-3, Survey Shows

Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel